Samsung Bioepis Co., Ltd. announced that Korea's Ministry of Food and Drug Safety (MFDS) has approved Renflexis – a biosimilar...
Samsung Bioepis Co., Ltd. announced that the FDA has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) , for the...
Merck Inc., hosted on 3 May an Organon management investor day meeting, to detail across women's health, biosimilars and established brands.
Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission...
Samsung Bioepis Co., Ltd. announced that the FDA has accepted for review the company�s Biologics License Application (BLA) for SB2,...
Samsung Bioepis Co. Ltd. announced that Health Canada has approved Ontruzant (also known as SB3), a biosimilar referencing Herceptin (Trastuzumab), for the treatment of adults with Early Breast Cancer (EBC), Metastatic Breast Cancer (MBC) and metastatic gastric cancer (MGC).
Organon celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange .